Neuritis

Global Optic Neuritis Treatment Market to Grow at a 4.1% CAGR Through 2027 - ResearchAndMarkets.com

Retrieved on: 
Friday, September 16, 2022
Optical, Health, COVID-19, Inflammation, Multiple sclerosis, Incidence, Journal, COVID-19, Woman, Optic neuritis, Brain, Prevalence, Sclerosis, Population, Journal of Neurologic Physical Therapy, Neuritis, Severe cognitive impairment, Eye, Steroid, Pain, Optic nerve, Awareness, Neurology, Color, Disease, Field line, CAGR, Telescopic sight, Dietary supplement, Medical imaging, Growth

The "Optic Neuritis Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Optic Neuritis Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)" report has been added to ResearchAndMarkets.com's offering.
  • The optic neuritis treatment market is expected to register a CAGR of 4.1% during the forecast period.
  • Rise in the geriatric population, increasing incidence of multiple sclerosis, and growing awareness about early detection of optic neuritis are the key driving factors of the optic neuritis treatment market.
  • According to the Optic Neuritis Foundation Inc, adults between the ages of 18-45 years are most prone to optic neuritis.

argenx Announces “GO” Decision in ADHERE Trial of Efgartigimod in Chronic Inflammatory Demyelinating Polyneuropathy Following Interim Analysis

Retrieved on: 
Monday, February 1, 2021
Branches of biology, Neurological disorders, Nervous system, Organ systems, Autoimmune diseases, Chronic inflammatory demyelinating polyneuropathy, Polyneuropathy, Peripheral neuropathy, Autoimmunity, Myelin, Autoimmune disease, Neuritis

The ADHERE trial is a randomized, withdrawal study evaluating 1000mg weekly subcutaneous (SC) efgartigimod for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP).

Key Points: 
  • The ADHERE trial is a randomized, withdrawal study evaluating 1000mg weekly subcutaneous (SC) efgartigimod for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP).
  • The trial consists of an open-label Stage A followed by a randomized, placebo-controlled Stage B with a planned interim responder analysis after the first 30 patients enroll in Stage A.
  • Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare and serious autoimmune disease of the peripheral nervous system.
  • argenx is evaluating efgartigimod in multiple serious autoimmune diseases, and cusatuzumab in hematological cancers in collaboration with Janssen.

Noveome Biotherapeutics, Inc. Announces Publication of Preclinical Results Demonstrating the Neuroprotective Properties of Amnion-derived Multipotent Progenitor Cells in Spinal Cord and Retinal Ganglion Cells

Retrieved on: 
Wednesday, October 21, 2020
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Genetics, Branches of biology, Nervous system, Neuroscience, Central nervous system disorders, Autoimmune diseases, Myelitis, Experimental autoimmune encephalomyelitis, Encephalomyelitis, Neuritis, Nerve, Spinal cord, Optic nerve

These new, peer-reviewed results demonstrate, for the first time, the neuroprotective properties of systemically delivered AMP cells in mice with experimental autoimmune encephalomyelitis (EAE)-induced experimental optic neuritis (ON) and myelitis.

Key Points: 
  • These new, peer-reviewed results demonstrate, for the first time, the neuroprotective properties of systemically delivered AMP cells in mice with experimental autoimmune encephalomyelitis (EAE)-induced experimental optic neuritis (ON) and myelitis.
  • All mice were sacrificed on day 42 post-immunization, and optic nerves and spinal cords were collected for analyses.
  • The hypothesis was that the cells would continue to secrete the secretome in vivo, thus acting like a delivery system.
  • We are pleased to see these preclinical results for the treatment of damaged optic nerves and spinal cord myelitis using systemically administered AMP cells.

Global Chronic Inflammatory Demyelinating Polyneuropathy Pipeline Report 2020: Therapeutic Analysis of 8 Companies, 4 Drug Profiles & Dormant Projects

Retrieved on: 
Friday, October 16, 2020
Branches of biology, Neuroscience, Neurological disorders, Organ systems, Autoimmune diseases, Chronic inflammatory demyelinating polyneuropathy, Polyneuropathy, Peripheral neuropathy, Myelin, Neuritis

Chronic Inflammatory Demyelinating Polyneuropathy - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Chronic Inflammatory Demyelinating Polyneuropathy (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

Key Points: 
  • Chronic Inflammatory Demyelinating Polyneuropathy - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Chronic Inflammatory Demyelinating Polyneuropathy (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • The Chronic Inflammatory Demyelinating Polyneuropathy (Central Nervous System) pipeline guide also reviews the key players involved in therapeutic development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and features dormant and discontinued projects.
  • The pipeline guide reviews pipeline therapeutics for Chronic Inflammatory Demyelinating Polyneuropathy (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Formulate corrective measures for pipeline projects by understanding Chronic Inflammatory Demyelinating Polyneuropathy (Central Nervous System) pipeline depth and focus of Indication therapeutics.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Pipeline Review, H2 2020 - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 8, 2020
General Health, Pharmaceutical, Health, Other Health, Branches of biology, Neuroscience, Neurological disorders, Organ systems, Autoimmune diseases, Chronic inflammatory demyelinating polyneuropathy, Polyneuropathy, Peripheral neuropathy, Myelin, Neuritis

The "Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline Review, H2 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline Review, H2 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Chronic Inflammatory Demyelinating Polyneuropathy - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Chronic Inflammatory Demyelinating Polyneuropathy (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • The Chronic Inflammatory Demyelinating Polyneuropathy (Central Nervous System) pipeline guide also reviews the key players involved in therapeutic development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and features dormant and discontinued projects.
  • Formulate corrective measures for pipeline projects by understanding Chronic Inflammatory Demyelinating Polyneuropathy (Central Nervous System) pipeline depth and focus of Indication therapeutics.

Global Pipeline Review for Optic Neuritis - H2 2019 - ResearchAndMarkets.com

Retrieved on: 
Monday, February 3, 2020
Pharmaceutical, Health, Optical, Optic neuritis, Neuritis

The "Optic Neuritis - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Optic Neuritis - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • The Optic Neuritis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Optic Neuritis and features dormant and discontinued projects.
  • Formulate corrective measures for pipeline projects by understanding Optic Neuritis (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

2018 Drug Development Pipeline Review for Optic Nerve Disorders (Optic Neuropathy, Glaucoma, LHON and Optic Neuritis)

Retrieved on: 
Friday, November 9, 2018
Nervous system, Peripheral nervous system, Vision, Optic neuropathy, Leber's hereditary optic neuropathy, Optic nerve, Nerve, Optic neuritis, Neuritis, Glaucoma, Mitochondrial optic neuropathies, Optic disc drusen

The "Optic Nerve Disorders Drug Development Pipeline Review, 2018" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Optic Nerve Disorders Drug Development Pipeline Review, 2018" report has been added to ResearchAndMarkets.com's offering.
  • This report provides an overview of the pipeline landscape for disorders of the optic nerve, the bundle of nerve fibers that transmits visual information from the eye to the brain.
  • It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for optic neuropathy, glaucoma, Leber's hereditary optic neuropathy (LHON) and optic neuritis, and features dormant and discontinued products.
  • Molecular targets acted on by products in development for optic nerve disorders include kinases, growth factors and cannabinoid receptors.